Bhatt, Anant Narayan http://orcid.org/0000-0001-5157-9719
Shenoy, Srinivas
Munjal, Sagar
Chinnadurai, Vijayakumar
Agarwal, Apurva
Vinoth Kumar, A.
Shanavas, A.
Kanwar, Ratnesh
Chandna, Sudhir
Funding for this research was provided by:
Institute of Nuclear Medicine and Allied Sciences, Defence Research and Development Organisation
Dr Reddy's Laboratries
Article History
Received: 13 December 2021
Accepted: 24 July 2022
First Online: 4 August 2022
Declarations
:
: The study protocol was approved by Drug Controller General of India (CTRI/2020/06/025664). The study was conducted at 12 hospitals located in various parts of India. Ethics Approval was obtained from respective Hospital’s Ethics committees (details can be obtained on this link: ExternalRef removed). Written informed consent was obtained from all study participants and the trial was conducted in accordance with the principles outlined in Declaration of Helsinki and Good Clinical Practice.
: Not applicable.
: Drs Anant Narayan Bhatt, Vijayakumar Chinnadurai, Ratnesh Kanwar and Sudhir Chandna: The authors (from INMAS-DRDO) have no conflict of interest or financial relationships relevant to the submitted work to disclose. None of the INMAS-DRDO authors accepted any honoraria or consultancy fees directly or indirectly from industry. Drs Srinivas Shenoy, Sagar Munjal and A Shanavas: The authors are paid employees of Dr Reddy’s Laboratories Limited. None of the authors received any separate compensation for the 2 DG project directly or indirectly. Dr Apurva Agarwal and Dr A Vinoth Kumar hereby certify that there is no actual or potential conflict of interest in relation to this article/publication of 2 DG study.